Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

Samsung Bioepis Enters into Partnership Agreement with Sandoz for Up to Five Next-Generation Biosimilar Candidates

Samsung Bioepis will develop and manufacture up to five biosimilars while Sandoz handles commercialization globally, excluding select Asian markets under a new agreement.

Summary by WBOC 16
The agreement covers up to five assets, including SB36, a biosimilar candidate referencing Entyvio (vedolizumab), for

8 Articles

WBOC 16WBOC 16
+5 Reposted by 5 other sources
Center

Samsung Bioepis Enters into Partnership Agreement with Sandoz for Up to Five Next-Generation Biosimilar Candidates

The agreement covers up to five assets, including SB36, a biosimilar candidate referencing Entyvio (vedolizumab), for

Read Full Article
EuropaWire.euEuropaWire.eu

Sandoz and Samsung Bioepis Expand Strategic Partnership to Advance Global Biosimilar Pipeline and Market Reach

Open the article to view the coverage from EuropaWire.eu

Read Full Article
pharmatimes.compharmatimes.com

Samsung Bioepis signs partnership with Sandoz for next‑generation biosimilars

Deal covers up to five candidates including SB36 as company expands global pipeline

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 67% of the sources are Center
67% Center

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

WBOC 16 broke the news in on Wednesday, March 18, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)

Similar News Topics

Samsung icon

Samsung

South Korea icon

South Korea

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal